|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
EXP |
gadobutrol results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:37437671 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
decreases expression |
EXP |
gadobutrol results in decreased expression of FABP4 mRNA |
CTD |
PMID:37437671 |
|
NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
decreases expression |
EXP |
gadobutrol results in decreased expression of PPARG mRNA |
CTD |
PMID:37437671 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
EXP |
gadodiamide results in decreased expression of ADIPOQ mRNA; gadodiamide results in decreased expression of ADIPOQ protein |
CTD |
PMID:37437671 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
increases phosphorylation multiple interactions |
ISO |
gadodiamide results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:19561517 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase family 1, subfamily A1 |
increases expression |
ISO |
gadodiamide results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829
|
|
G |
Ankrd22 |
ankyrin repeat domain 22 |
increases expression |
ISO |
gadodiamide results in increased expression of ANKRD22 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr19:34,099,949...34,143,441
Ensembl chr19:34,098,869...34,143,453
|
|
G |
Atm |
ataxia telangiectasia mutated |
increases expression |
ISO |
gadodiamide results in increased expression of ATM mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040
|
|
G |
Atp8b1 |
ATPase, class I, type 8B, member 1 |
increases expression |
ISO |
gadodiamide results in increased expression of ATP8B1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr18:64,662,050...64,794,342
Ensembl chr18:64,662,038...64,794,338
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression increases secretion |
ISO |
gadodiamide results in increased expression of CCL2 mRNA gadodiamide results in increased expression of CCL2 mRNA; gadodiamide results in increased expression of CCL2 protein gadodiamide results in increased secretion of CCL2 protein |
CTD |
PMID:20938346 PMID:20959327 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression |
ISO |
gadodiamide results in increased expression of CCL4 protein |
CTD |
PMID:20938346 |
|
NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
ISO |
gadodiamide results in increased expression of CCL7 protein |
CTD |
PMID:20938346 |
|
NCBI chr11:81,936,538...81,938,351
Ensembl chr11:81,936,538...81,938,351
|
|
G |
Ccl8 |
C-C motif chemokine ligand 8 |
increases secretion increases expression |
ISO |
gadodiamide results in increased secretion of CCL8 protein gadodiamide results in increased expression of CCL8 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr11:82,006,011...82,007,625
Ensembl chr11:82,006,011...82,007,625
|
|
G |
Cep15 |
centrosomal protein 15 |
increases expression |
ISO |
gadodiamide results in increased expression of CEP15 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr14:10,147,278...10,185,610
Ensembl chr14:10,166,532...10,185,590 Ensembl chr14:10,166,532...10,185,590
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression increases secretion |
ISO |
gadodiamide results in increased expression of CXCL10 mRNA gadodiamide results in increased expression of CXCL10 protein gadodiamide results in increased secretion of CXCL10 protein |
CTD |
PMID:20938346 PMID:20959327 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl11 |
chemokine (C-X-C motif) ligand 11 |
increases secretion increases expression |
ISO |
gadodiamide results in increased secretion of CXCL11 protein gadodiamide results in increased expression of CXCL11 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 5:92,507,403...92,511,155
Ensembl chr 5:92,507,403...92,513,344
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
ISO |
gadodiamide results in increased expression of CXCL12 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
increases expression |
ISO |
gadodiamide results in increased expression of CXCL9 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 5:92,469,190...92,475,938
Ensembl chr 5:92,469,206...92,475,938
|
|
G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
decreases expression |
EXP |
gadodiamide results in decreased expression of FABP4 mRNA; gadodiamide results in decreased expression of FABP4 protein |
CTD |
PMID:37437671 |
|
NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
increases expression |
ISO |
gadodiamide results in increased expression of IDO1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 8:25,074,148...25,086,987
Ensembl chr 8:25,074,152...25,087,025
|
|
G |
Ifi44l |
interferon-induced protein 44 like |
increases expression |
ISO |
gadodiamide results in increased expression of IFI44L mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 3:151,464,374...151,468,528
Ensembl chr 3:151,464,374...151,468,529
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
increases expression |
ISO |
gadodiamide results in increased expression of IFIT3 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr19:34,560,519...34,566,382
Ensembl chr19:34,560,931...34,566,131
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
gadodiamide results in increased expression of IFNG mRNA; gadodiamide results in increased expression of IFNG protein |
CTD |
PMID:19404939 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Il13 |
interleukin 13 |
increases expression |
ISO |
gadodiamide results in increased expression of IL13 mRNA; gadodiamide results in increased expression of IL13 protein |
CTD |
PMID:19404939 |
|
NCBI chr11:53,522,150...53,525,529
Ensembl chr11:53,522,151...53,525,529
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
gadodiamide results in increased expression of IL1A protein |
CTD |
PMID:20938346 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il4 |
interleukin 4 |
increases expression affects expression |
ISO |
gadodiamide results in increased expression of IL4 protein gadodiamide affects the expression of IL4 mRNA |
CTD |
PMID:19404939 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il4i1 |
interleukin 4 induced 1 |
increases expression |
ISO |
gadodiamide results in increased expression of IL4I1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 7:44,485,712...44,490,233
Ensembl chr 7:44,465,811...44,490,233
|
|
G |
Il6 |
interleukin 6 |
affects expression increases expression |
ISO |
gadodiamide affects the expression of IL6 protein gadodiamide results in increased expression of IL6 mRNA |
CTD |
PMID:19404939 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Kitl |
kit ligand |
increases expression |
ISO |
gadodiamide results in increased expression of KITLG protein |
CTD |
PMID:20938346 |
|
NCBI chr10:99,851,477...99,936,278
Ensembl chr10:99,851,492...99,936,278
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19561517 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19561517 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mmp1b |
matrix metallopeptidase 1b (interstitial collagenase) |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of MMP1 protein] gadodiamide results in increased expression of MMP1 mRNA; gadodiamide results in increased expression of MMP1 protein |
CTD |
PMID:19561517 |
|
NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
increases expression |
ISO |
gadodiamide results in increased expression of NOS2 protein |
CTD |
PMID:20959327 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nxpe3 |
neurexophilin and PC-esterase domain family, member 3 |
increases expression |
ISO |
gadodiamide results in increased expression of NXPE3 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr16:55,660,316...55,717,467
Ensembl chr16:55,660,316...55,715,648
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
decreases expression |
EXP |
gadodiamide results in decreased expression of PPARG mRNA; gadodiamide results in decreased expression of PPARG protein |
CTD |
PMID:37437671 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
increases localization |
ISO |
gadodiamide results in increased localization of RELA protein |
CTD |
PMID:20959327 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rhoq |
ras homolog family member Q |
increases expression |
ISO |
gadodiamide results in increased expression of RHOQ mRNA |
CTD |
PMID:20959327 |
|
NCBI chr17:87,270,539...87,307,497
Ensembl chr17:87,270,510...87,307,497
|
|
G |
Rit1 |
Ras-like without CAAX 1 |
increases expression |
ISO |
gadodiamide results in increased expression of RIT1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 3:88,624,154...88,638,354
Ensembl chr 3:88,624,145...88,638,356
|
|
G |
Rnf125 |
ring finger protein 125 |
increases expression |
ISO |
gadodiamide results in increased expression of RNF125 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr18:21,077,672...21,120,416
Ensembl chr18:21,077,682...21,116,919
|
|
G |
Rsad2 |
radical S-adenosyl methionine domain containing 2 |
increases expression |
ISO |
gadodiamide results in increased expression of RSAD2 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr12:26,492,742...26,506,451
Ensembl chr12:26,492,745...26,506,451
|
|
G |
Rsl1 |
regulator of sex limited protein 1 |
increases expression |
ISO |
gadodiamide results in increased expression of ZNF595 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr13:67,321,238...67,332,108
Ensembl chr13:67,321,195...67,332,108
|
|
G |
Slc39a10 |
solute carrier family 39 (zinc transporter), member 10 |
increases expression |
ISO |
gadodiamide results in increased expression of SLC39A10 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 1:46,846,704...46,964,952
Ensembl chr 1:46,846,704...46,932,012
|
|
G |
Spn |
sialophorin |
increases expression |
ISO |
gadodiamide results in increased expression of SPN mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 7:126,731,404...126,743,785
Ensembl chr 7:126,731,404...126,736,995
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
gadodiamide results in increased expression of SPP1 protein |
CTD |
PMID:20938346 |
|
NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
gadodiamide results in increased expression of TGFB1 mRNA; gadodiamide results in increased expression of TGFB1 protein |
CTD |
PMID:19404939 PMID:20938346 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
increases expression multiple interactions |
ISO |
gadodiamide results in increased expression of TIMP1 mRNA; gadodiamide results in increased expression of TIMP1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [gadodiamide results in increased expression of TIMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of TIMP1 protein] |
CTD |
PMID:19561517 PMID:20938346 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Ubd |
ubiquitin D |
increases expression |
ISO |
gadodiamide results in increased expression of UBD mRNA |
CTD |
PMID:20959327 |
|
NCBI chr17:37,504,783...37,506,992
Ensembl chr17:37,504,783...37,506,986
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
gadodiamide results in increased expression of VEGFA mRNA; gadodiamide results in increased expression of VEGFA protein |
CTD |
PMID:19404939 PMID:20938346 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Wdr5 |
WD repeat domain 5 |
increases expression |
ISO |
gadodiamide results in increased expression of WDR5 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 2:27,405,159...27,426,547
Ensembl chr 2:27,405,169...27,426,547
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
increases expression |
ISO |
gadodiamide results in increased expression of XIAP mRNA |
CTD |
PMID:20959327 |
|
NCBI chr X:41,148,483...41,198,541
Ensembl chr X:41,148,556...41,198,533
|
|
G |
Zfp652 |
zinc finger protein 652 |
increases expression |
ISO |
gadodiamide results in increased expression of ZNF652 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr11:95,639,893...95,655,541
Ensembl chr11:95,603,499...95,725,941
|
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C member 4 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [perfluorodecanoic acid results in increased expression of ABCC4 mRNA] |
CTD |
PMID:18757529 |
|
NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
|
|
G |
Acaca |
acetyl-Coenzyme A carboxylase alpha |
multiple interactions |
EXP ISO |
gadolinium chloride promotes the reaction [Ethanol results in decreased expression of ACACA protein] [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of ACACA mRNA |
CTD |
PMID:28882574 PMID:34878122 |
|
NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
multiple interactions |
ISO |
gadolinium chloride promotes the reaction [perfluoro-n-nonanoic acid results in increased expression of ACOT1 mRNA] |
CTD |
PMID:22648072 |
|
NCBI chr12:84,056,276...84,064,444
Ensembl chr12:84,056,264...84,065,145
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:11408273 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
ISO EXP |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of ADGRE1 mRNA gadolinium chloride inhibits the reaction [Ethanol results in increased expression of ADGRE1 protein] |
CTD |
PMID:25813056 PMID:28882574 |
|
NCBI chr17:57,665,650...57,790,527
Ensembl chr17:57,665,691...57,790,527
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
EXP |
gadolinium chloride results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:37437671 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
ISO |
gadolinium chloride promotes the reaction [[Fructose co-treated with Copper deficiency] results in decreased expression of APOB mRNA] |
CTD |
PMID:25813056 |
|
NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835
|
|
G |
Atf4 |
activating transcription factor 4 |
affects expression |
ISO |
gadolinium chloride affects the expression of ATF4 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions increases expression affects expression |
ISO |
Acetylcysteine inhibits the reaction [gadolinium chloride results in increased expression of ATF6 protein] gadolinium chloride affects the expression of ATF6 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in decreased expression of BCL2 protein |
CTD |
PMID:34878122 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of BMAL1 protein |
CTD |
PMID:34878122 |
|
NCBI chr 7:112,777,820...112,913,333
Ensembl chr 7:112,806,672...112,913,333
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
gadolinium chloride promotes the reaction [Carbon Tetrachloride results in increased expression of BMP2 mRNA] |
CTD |
PMID:17158861 |
|
NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of CASP3 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [[Triiodothyronine co-treated with Hexachlorocyclohexane] results in decreased activity of CAT protein] |
CTD |
PMID:12516873 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CCL2 mRNA]; gadolinium chloride inhibits the reaction [[Fructose co-treated with Copper deficiency] results in increased expression of CCL2 protein] |
CTD |
PMID:25813056 PMID:26177832 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO |
gadolinium chloride results in increased expression of CCNE1 |
CTD |
PMID:19184457 |
|
NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959
|
|
G |
Cd163 |
CD163 antigen |
multiple interactions |
ISO |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of CD163 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA] |
CTD |
PMID:25813056 PMID:26177832 |
|
NCBI chr 6:124,281,596...124,307,488
Ensembl chr 6:124,281,615...124,307,486
|
|
G |
Cd68 |
CD68 antigen |
multiple interactions |
EXP ISO |
gadolinium chloride inhibits the reaction [[Dietary Fats co-treated with bromodichloromethane] results in increased expression of CD68 mRNA] [gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of CD68 mRNA; [gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of CD68 protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD68 mRNA] |
CTD |
PMID:23438451 PMID:25813056 PMID:26177832 |
|
NCBI chr11:69,555,039...69,556,996
Ensembl chr11:69,555,039...69,556,979
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
multiple interactions |
ISO |
gadolinium chloride promotes the reaction [perfluoro-n-nonanoic acid results in increased expression of CPT1A mRNA] [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of CPT1A mRNA |
CTD |
PMID:22648072 PMID:34878122 |
|
NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL1 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
EXP ISO |
gadolinium chloride inhibits the reaction [[Progesterone co-treated with Halothane] results in increased expression of CXCL2 mRNA] gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL2 mRNA] |
CTD |
PMID:22157104 PMID:26177832 |
|
NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Progesterone promotes the reaction [Halothane results in increased expression of CXCL1 mRNA]]; gadolinium chloride inhibits the reaction [Progesterone results in increased expression of CXCL1 mRNA] |
CTD |
PMID:22157104 |
|
NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP1A2 protein] |
CTD |
PMID:18202523 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp2b13 |
cytochrome P450, family 2, subfamily b, polypeptide 13 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2B2 mRNA]; gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2B2 protein] |
CTD |
PMID:18202523 |
|
NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622
|
|
G |
Cyp2c52-ps |
cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased activity of and results in decreased expression of CYP2C11 protein] |
CTD |
PMID:18079364 |
|
NCBI chr19:38,965,106...38,992,071
Ensembl chr19:38,965,091...38,991,733
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2E1 mRNA]; gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2E1 protein] |
CTD |
PMID:18202523 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Cyp4a12b |
cytochrome P450, family 4, subfamily a, polypeptide 12B |
multiple interactions |
ISO |
gadolinium chloride promotes the reaction [[Fructose co-treated with Copper deficiency] results in decreased expression of CYP4A1 mRNA] |
CTD |
PMID:25813056 |
|
NCBI chr 4:115,268,821...115,296,231
Ensembl chr 4:115,268,821...115,296,231
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression affects expression |
ISO |
Acetylcysteine inhibits the reaction [gadolinium chloride results in increased expression of DDIT3 protein] gadolinium chloride affects the expression of DDIT3 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression |
ISO |
gadolinium chloride results in increased expression of EIF2AK3 protein |
CTD |
PMID:21198628 |
|
NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signalling 1 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [gadolinium chloride results in increased expression of ERN1 protein] |
CTD |
PMID:21198628 |
|
NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678
|
|
G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
decreases expression |
EXP |
gadolinium chloride results in decreased expression of FABP4 mRNA |
CTD |
PMID:37437671 |
|
NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO EXP |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of FASN mRNA gadolinium chloride promotes the reaction [Ethanol results in decreased expression of FASN protein] |
CTD |
PMID:25813056 PMID:28882574 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO EXP |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of GPT protein]; gadolinium chloride inhibits the reaction [Vitamin A results in increased activity of GPT protein] gadolinium chloride inhibits the reaction [Amiodarone promotes the reaction [Dexamethasone results in increased expression of GPT protein]] |
CTD |
PMID:8627517 PMID:25900201 PMID:26177832 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression |
ISO |
gadolinium chloride results in increased expression of HAMP |
CTD |
PMID:19721414 |
|
NCBI chr 7:30,641,793...30,643,454
Ensembl chr 7:30,641,793...30,643,457
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of HIF1A mRNA |
CTD |
PMID:34878122 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hjv |
hemojuvelin BMP co-receptor |
decreases expression |
ISO |
gadolinium chloride results in decreased expression of HJV |
CTD |
PMID:19721414 |
|
NCBI chr 3:96,432,479...96,436,532
Ensembl chr 3:96,432,488...96,436,526
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased secretion of HMGB1 protein] |
CTD |
PMID:26177832 |
|
NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 |
multiple interactions |
ISO |
gadolinium chloride promotes the reaction [[Fructose co-treated with Copper deficiency] results in decreased expression of HMGCS2 mRNA] |
CTD |
PMID:25813056 |
|
NCBI chr 3:98,187,747...98,218,054
Ensembl chr 3:98,187,751...98,218,054
|
|
G |
Hspa1a |
heat shock protein 1A |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of HSPA1A mRNA]; gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of HSPA1A protein] |
CTD |
PMID:12963478 |
|
NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132
|
|
G |
Hspa5 |
heat shock protein 5 |
increases expression multiple interactions affects expression |
ISO |
gadolinium chloride results in increased expression of HSPA5 protein Acetylcysteine inhibits the reaction [gadolinium chloride results in increased expression of HSPA5 protein] gadolinium chloride affects the expression of HSPA5 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Progesterone co-treated with Halothane] results in increased expression of ICAM1 mRNA] |
CTD |
PMID:22157104 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Ifng |
interferon gamma |
affects expression increases expression |
ISO EXP |
gadolinium chloride affects the expression of IFNG protein gadolinium chloride results in increased expression of IFNG mRNA |
CTD |
PMID:15590129 PMID:19404939 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Lipopolysaccharides results in decreased expression of IGF1 protein] |
CTD |
PMID:16522730 |
|
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Lipopolysaccharides results in decreased expression of IGFBP3 protein] |
CTD |
PMID:16522730 |
|
NCBI chr11:7,156,086...7,165,498
Ensembl chr11:7,156,086...7,163,923
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL10 mRNA]; gadolinium chloride inhibits the reaction [perfluoro-n-nonanoic acid results in decreased expression of IL10 protein] |
CTD |
PMID:22648072 PMID:26177832 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il13 |
interleukin 13 |
increases expression |
ISO |
gadolinium chloride results in increased expression of IL13 mRNA |
CTD |
PMID:19404939 |
|
NCBI chr11:53,522,150...53,525,529
Ensembl chr11:53,522,151...53,525,529
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased expression of IL1A mRNA]; gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased expression of IL1A protein] |
CTD |
PMID:15025948 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
ISO |
gadolinium chloride results in increased expression of IL1B [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of IL1B mRNA [gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of IL1B mRNA; gadolinium chloride inhibits the reaction [perfluoro-n-nonanoic acid results in increased expression of IL1B protein] |
CTD |
PMID:19721414 PMID:22648072 PMID:25813056 PMID:34878122 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il4 |
interleukin 4 |
affects expression |
ISO |
gadolinium chloride affects the expression of IL4 mRNA; gadolinium chloride affects the expression of IL4 protein |
CTD |
PMID:19404939 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of IL6 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL6 mRNA]; gadolinium chloride inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of IL6 mRNA gadolinium chloride inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] gadolinium chloride results in increased expression of IL6 gadolinium chloride results in increased expression of IL6 mRNA |
CTD |
PMID:12127824 PMID:12963478 PMID:19404939 PMID:19721414 PMID:24849676 PMID:25813056 PMID:26177832 PMID:34878122 More...
|
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Lipe |
lipase, hormone sensitive |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Ethanol results in increased phosphorylation of LIPE protein] |
CTD |
PMID:28882574 |
|
NCBI chr 7:25,078,952...25,097,911
Ensembl chr 7:25,078,952...25,098,135
|
|
G |
Ltb |
lymphotoxin B |
increases expression |
EXP |
gadolinium chloride results in increased expression of LTB mRNA |
CTD |
PMID:15590129 |
|
NCBI chr17:35,413,483...35,415,281
Ensembl chr17:35,413,415...35,415,296
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
decreases phosphorylation multiple interactions increases activity |
ISO |
gadolinium chloride results in decreased phosphorylation of MAPK1 protein gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK1 protein] gadolinium chloride results in increased activity of MAPK1 protein Pertussis Toxin inhibits the reaction [gadolinium chloride results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:12493575 PMID:21605080 PMID:26177832 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
decreases phosphorylation multiple interactions increases activity |
ISO |
gadolinium chloride results in decreased phosphorylation of MAPK3 protein gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK3 protein] Pertussis Toxin inhibits the reaction [gadolinium chloride results in decreased phosphorylation of MAPK3 protein] gadolinium chloride results in increased activity of MAPK3 protein |
CTD |
PMID:12493575 PMID:21605080 PMID:26177832 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions increases expression |
ISO |
[Dimethylnitrosamine co-treated with gadolinium chloride] results in increased expression of MMP13 mRNA; SB 203580 inhibits the reaction [gadolinium chloride results in increased expression of MMP13 mRNA] |
CTD |
PMID:12493575 |
|
NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331
|
|
G |
Mmp14 |
matrix metallopeptidase 14 (membrane-inserted) |
multiple interactions increases expression |
ISO |
[Dimethylnitrosamine co-treated with gadolinium chloride] results in increased expression of MMP14 mRNA gadolinium chloride results in increased expression of MMP14 mRNA; gadolinium chloride results in increased expression of MMP14 protein |
CTD |
PMID:12493575 |
|
NCBI chr14:54,669,055...54,679,913
Ensembl chr14:54,669,069...54,682,821
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
ISO |
gadolinium chloride results in increased expression of MMP9 mRNA SB 203580 inhibits the reaction [gadolinium chloride results in increased expression of MMP9 mRNA] |
CTD |
PMID:12493575 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Thioacetamide results in increased activity of MPO protein] |
CTD |
PMID:12963478 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of NFE2L2 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased activity of NFKB1 protein] [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of NFKB1 mRNA |
CTD |
PMID:15025948 PMID:34878122 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
increases expression |
ISO |
gadolinium chloride results in increased expression of NOS2 mRNA |
CTD |
PMID:15135310 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Pdgfa |
platelet derived growth factor, alpha |
decreases expression |
ISO |
gadolinium chloride results in decreased expression of PDGFA mRNA |
CTD |
PMID:14578756 |
|
NCBI chr 5:138,961,761...138,986,336
Ensembl chr 5:138,961,769...138,983,125
|
|
G |
Pdgfb |
platelet derived growth factor, B polypeptide |
decreases expression |
ISO |
gadolinium chloride results in decreased expression of PDGFB mRNA |
CTD |
PMID:14578756 |
|
NCBI chr15:79,880,066...79,899,178
Ensembl chr15:79,880,075...79,899,178
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
gadolinium chloride promotes the reaction [perfluoro-n-nonanoic acid results in increased expression of PPARA mRNA] |
CTD |
PMID:22648072 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
decreases expression |
EXP |
gadolinium chloride results in decreased expression of PPARG mRNA |
CTD |
PMID:37437671 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ptk2 |
PTK2 protein tyrosine kinase 2 |
increases activity |
ISO |
gadolinium chloride results in increased activity of PTK2 |
CTD |
PMID:19184457 |
|
NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases phosphorylation |
ISO |
gadolinium chloride results in increased phosphorylation of RB1 protein |
CTD |
PMID:19184457 |
|
NCBI chr14:73,430,298...73,563,446
Ensembl chr14:73,421,113...73,563,262
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased activity of RELA protein] [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of RELA protein |
CTD |
PMID:15025948 PMID:34878122 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
S100a8 |
S100 calcium binding protein A8 (calgranulin A) |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A8 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342
|
|
G |
S100a9 |
S100 calcium binding protein A9 (calgranulin B) |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A9 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr 3:90,599,937...90,603,028
Ensembl chr 3:90,599,939...90,603,028
|
|
G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
multiple interactions |
ISO EXP |
gadolinium chloride promotes the reaction [[Fructose co-treated with Copper deficiency] results in decreased expression of SCD1 mRNA] gadolinium chloride promotes the reaction [Ethanol results in decreased expression of SCD1 protein] |
CTD |
PMID:25813056 PMID:28882574 |
|
NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318
|
|
G |
Slc40a1 |
solute carrier family 40 (iron-regulated transporter), member 1 |
decreases expression |
ISO |
gadolinium chloride results in decreased expression of SLC40A1 |
CTD |
PMID:19721414 |
|
NCBI chr 1:45,947,230...45,965,690
Ensembl chr 1:45,947,228...45,965,683
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of SPP1 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of SQSTM1 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [[Fructose co-treated with Copper deficiency] results in increased expression of SREBF1 protein] |
CTD |
PMID:25813056 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression affects expression |
ISO EXP |
gadolinium chloride inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; gadolinium chloride inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]; gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA] [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of TGFB1 mRNA gadolinium chloride results in increased expression of TGFB1 protein gadolinium chloride results in increased expression of TGFB1 mRNA gadolinium chloride affects the expression of TGFB1 mRNA |
CTD |
PMID:11408273 PMID:15590129 PMID:15964588 PMID:19404939 PMID:34878122 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of TLR4 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TLR4 protein] |
CTD |
PMID:25813056 PMID:26177832 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression increases expression |
ISO EXP |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of TNF mRNA; gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased expression of TNF mRNA]; gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased expression of TNF protein]; gadolinium chloride inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; gadolinium chloride inhibits the reaction [perfluoro-n-nonanoic acid results in increased expression of TNF protein]; gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of TNF protein] gadolinium trichloride inhibits the reaction [estriol enhances the reaction [lipopolysaccharide increases expression of Tnf mRNA in liver]] gadolinium chloride inhibits the reaction [lead acetate promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; gadolinium chloride inhibits the reaction [perfluorodecanoic acid results in increased expression of TNF protein] gadolinium chloride results in increased expression of TNF gadolinium chloride results in increased expression of TNF mRNA |
CTD RGD |
PMID:12127824 PMID:12963478 PMID:14687926 PMID:15025948 PMID:15590129 PMID:16581537 PMID:18757529 PMID:19721414 PMID:22648072 PMID:25813056 PMID:9575848 More...
|
RGD:15017096 |
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) |
increases expression |
ISO |
gadolinium chloride results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:21605080 |
|
NCBI chr15:54,114,014...54,141,700
Ensembl chr15:54,114,015...54,141,880
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
increases expression |
EXP |
gadolinium chloride results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:15590129 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
increases expression |
EXP |
gadolinium chloride results in increased expression of TNFSF10 mRNA |
CTD |
PMID:15590129 |
|
NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
decreases expression |
ISO |
gadolinium chloride results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:21605080 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
G |
Ucp2 |
uncoupling protein 2 (mitochondrial, proton carrier) |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Carbon Tetrachloride results in increased expression of UCP2 mRNA] |
CTD |
PMID:18314881 |
|
NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
gadolinium chloride results in increased expression of VEGFA mRNA; gadolinium chloride results in increased expression of VEGFA protein |
CTD |
PMID:19404939 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases splicing |
ISO |
gadolinium chloride results in increased splicing of XBP1 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893
|
|
|
G |
Agl |
amylo-1,6-glucosidase, 4-alpha-glucanotransferase |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of AGL mRNA motexafin gadolinium results in decreased expression of AGL mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:116,533,648...116,601,815
Ensembl chr 3:116,533,648...116,601,815
|
|
G |
Aldh5a1 |
aldhehyde dehydrogenase family 5, subfamily A1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of ALDH5A1 mRNA] motexafin gadolinium results in increased expression of ALDH5A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr13:25,091,562...25,121,740
Ensembl chr13:25,091,562...25,121,644 Ensembl chr13:25,091,562...25,121,644
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase family 6, subfamily A1 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ALDH6A1 mRNA Zinc Acetate inhibits the reaction [motexafin gadolinium results in decreased expression of ALDH6A1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr12:84,477,491...84,497,798
Ensembl chr12:84,477,491...84,497,778
|
|
G |
Arhgap17 |
Rho GTPase activating protein 17 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ARHGAP17 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ARHGAP17 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:122,878,372...122,969,171
Ensembl chr 7:122,878,441...122,969,138
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of ATF3 mRNA] motexafin gadolinium results in increased expression of ATF3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236
|
|
G |
Atm |
ataxia telangiectasia mutated |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of ATM mRNA] motexafin gadolinium results in increased expression of ATM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040
|
|
G |
Atr |
ataxia telangiectasia and Rad3 related |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ATR mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ATR mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:95,739,655...95,834,813
Ensembl chr 9:95,739,650...95,833,834
|
|
G |
Bach1 |
BTB and CNC homology 1, basic leucine zipper transcription factor 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of BACH1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BACH1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:87,495,842...87,530,234
Ensembl chr16:87,495,833...87,530,234
|
|
G |
Bag3 |
BCL2-associated athanogene 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of BAG3 mRNA] motexafin gadolinium results in increased expression of BAG3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:128,125,307...128,148,705
Ensembl chr 7:128,125,340...128,148,705
|
|
G |
Bbc3 |
BCL2 binding component 3 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein] |
CTD |
PMID:20530418 |
|
NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of BIRC5 mRNA] motexafin gadolinium results in increased expression of BIRC5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Bnip3 |
BCL2/adenovirus E1B interacting protein 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of BNIP3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BNIP3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248
|
|
G |
Bnip3l |
BCL2/adenovirus E1B interacting protein 3-like |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of BNIP3L mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BNIP3L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:67,222,688...67,246,580
Ensembl chr14:67,222,688...67,246,326
|
|
G |
Canx |
calnexin |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CANX mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CANX mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:50,184,784...50,216,500
Ensembl chr11:50,184,788...50,216,500
|
|
G |
Casp3 |
caspase 3 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CASP3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CASP3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cbfb |
core binding factor beta |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CBFB mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CBFB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:105,897,306...105,944,621
Ensembl chr 8:105,897,306...105,944,621
|
|
G |
Ccnj |
cyclin J |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CCNJ mRNA motexafin gadolinium results in decreased expression of CCNJ mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:40,819,345...40,837,016
Ensembl chr19:40,819,723...40,837,016
|
|
G |
Cdc16 |
CDC16 cell division cycle 16 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CDC16 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDC16 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:13,807,650...13,831,951
Ensembl chr 8:13,807,676...13,831,938
|
|
G |
Cdc25c |
cell division cycle 25C |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CDC25C mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CDC25C mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:34,866,046...34,884,644
Ensembl chr18:34,866,046...34,884,586
|
|
G |
Cdc27 |
cell division cycle 27 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CDC27 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CDC27 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:104,393,350...104,441,371
Ensembl chr11:104,393,571...104,441,446
|
|
G |
Cdc5l |
cell division cycle 5-like |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CDC5L mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDC5L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:45,702,809...45,744,633
Ensembl chr17:45,702,810...45,744,663
|
|
G |
Cdca2 |
cell division cycle associated 2 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CDCA2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDCA2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:67,910,629...67,953,290
Ensembl chr14:67,913,780...67,953,290
|
|
G |
Cdk19 |
cyclin dependent kinase 19 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of CDK19 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:40,225,283...40,359,814
Ensembl chr10:40,215,560...40,359,814
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of CDK2 mRNA] motexafin gadolinium results in increased expression of CDK2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA] |
CTD |
PMID:20530418 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CDKN1B mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CDKN1B mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cth |
cystathionine gamma lyase |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CTH mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CTH mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:157,599,885...157,630,718
Ensembl chr 3:157,599,885...157,630,714
|
|
G |
Cul3 |
cullin 3 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CUL3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CUL3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:80,242,640...80,318,426
Ensembl chr 1:80,242,640...80,318,197
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CYB5R1 mRNA motexafin gadolinium results in increased expression of CYB5R1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:134,333,519...134,339,476
Ensembl chr 1:134,333,297...134,339,478
|
|
G |
Dapk3 |
death-associated protein kinase 3 |
multiple interactions decreases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DAPK3 mRNA] motexafin gadolinium results in decreased expression of DAPK3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:81,018,821...81,029,031
Ensembl chr10:81,018,839...81,029,031
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DDIT3 mRNA] motexafin gadolinium results in increased expression of DDIT3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of DDIT4 mRNA motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of DDIT4 mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of DDIT4 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr10:59,785,497...59,787,592
Ensembl chr10:59,785,491...59,787,656
|
|
G |
Dedd2 |
death effector domain-containing DNA binding protein 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DEDD2 mRNA] motexafin gadolinium results in increased expression of DEDD2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:24,899,337...24,920,035
Ensembl chr 7:24,899,340...24,920,040
|
|
G |
Dffb |
DNA fragmentation factor, beta subunit |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of DFFB mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of DFFB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:154,048,904...154,059,578
Ensembl chr 4:154,048,906...154,059,583
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of DHCR7 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:143,376,827...143,402,147
Ensembl chr 7:143,376,882...143,402,147
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in decreased expression of DNAJB1 mRNA] motexafin gadolinium results in increased expression of DNAJB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:84,334,804...84,339,282
Ensembl chr 8:84,334,822...84,339,282
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of DNAJB4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of DNAJB4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:151,887,217...151,915,720
Ensembl chr 3:151,884,148...151,915,939
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of DNAJB6 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of DNAJB6 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:29,940,896...29,991,476
Ensembl chr 5:29,940,686...30,023,132
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of DNAJC3 mRNA] motexafin gadolinium results in increased expression of DNAJC3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:119,175,371...119,219,114
Ensembl chr14:119,175,388...119,219,109
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F1 mRNA motexafin gadolinium results in increased expression of E2F1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812
|
|
G |
E2f3 |
E2F transcription factor 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of E2F3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr13:30,090,558...30,171,172
Ensembl chr13:30,090,558...30,170,046
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of EGLN1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of EGLN1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:125,635,325...125,676,063
Ensembl chr 8:125,635,326...125,676,063
|
|
G |
Elp1 |
elongator complex protein 1 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ELP1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ELP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:56,746,547...56,802,565
Ensembl chr 4:56,749,680...56,802,331
|
|
G |
Eno1 |
enolase 1, alpha non-neuron |
increases expression |
ISO |
motexafin gadolinium results in increased expression of ENO1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336 Ensembl chr18:150,321,178...150,333,336
|
|
G |
Fadd |
Fas associated via death domain |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of FADD mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of FADD mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:144,132,060...144,136,178
Ensembl chr 7:144,131,055...144,136,200
|
|
G |
Faim |
Fas apoptotic inhibitory molecule |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of FAIM mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of FAIM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:98,868,426...98,884,076
Ensembl chr 9:98,868,426...98,884,074
|
|
G |
Fam162a |
family with sequence similarity 162, member A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of FAM162A mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of FAM162A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:35,864,214...35,891,931
Ensembl chr16:35,864,131...35,891,964
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of FASN mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Foxo3 |
forkhead box O3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of FOXO3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of FOXO3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of GCLM mRNA motexafin gadolinium results in increased expression of GCLM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gls |
glutaminase |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of GLS mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GLS mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:52,202,608...52,274,168
Ensembl chr 1:52,202,607...52,272,391
|
|
G |
Gpr146 |
G protein-coupled receptor 146 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of GPR146 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:139,363,452...139,382,170
Ensembl chr 5:139,363,452...139,382,170
|
|
G |
Gpt2 |
glutamic pyruvate transaminase (alanine aminotransferase) 2 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of GPT2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:86,219,090...86,255,531
Ensembl chr 8:86,219,205...86,254,189
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA] |
CTD |
PMID:20530418 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gsr |
glutathione reductase |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of GSR mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of GSR mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Gtf3c2 |
general transcription factor IIIC, polypeptide 2, beta |
increases expression |
ISO |
motexafin gadolinium results in increased expression of GTF3C2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:31,313,350...31,337,488
Ensembl chr 5:31,313,349...31,337,488
|
|
G |
Hbp1 |
high mobility group box transcription factor 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HBP1 mRNA motexafin gadolinium results in increased expression of HBP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:31,976,449...32,000,529
Ensembl chr12:31,976,253...32,000,534
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
multiple interactions increases expression |
ISO |
[motexafin gadolinium co-treated with Zinc Acetate] results in increased expression of HIF1A protein motexafin gadolinium results in increased expression of HIF1A protein |
CTD |
PMID:16357179 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hilpda |
hypoxia inducible lipid droplet associated |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HILPDA mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HILPDA mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:29,272,487...29,275,448
Ensembl chr 6:29,272,487...29,275,445
|
|
G |
Hipk1 |
homeodomain interacting protein kinase 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HIPK1 mRNA] motexafin gadolinium results in increased expression of HIPK1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:103,647,131...103,699,210
Ensembl chr 3:103,647,131...103,698,879
|
|
G |
Hltf |
helicase-like transcription factor |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of HLTF mRNA motexafin gadolinium results in decreased expression of HLTF mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:20,111,959...20,172,655
Ensembl chr 3:20,111,975...20,172,654
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[motexafin gadolinium co-treated with Zinc Acetate] results in increased expression of HMOX1 protein; motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HMOX1 mRNA] motexafin gadolinium results in increased expression of HMOX1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hrk |
harakiri, BCL2 interacting protein (contains only BH3 domain) |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HRK mRNA motexafin gadolinium results in increased expression of HRK mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:118,307,829...118,327,543
Ensembl chr 5:118,302,713...118,327,543
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha (cytosolic), class B member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSP90AB1 mRNA motexafin gadolinium results in increased expression of HSP90AB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:45,878,704...45,884,187
Ensembl chr17:45,878,701...45,884,197
|
|
G |
Hspa1a |
heat shock protein 1A |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPA1A mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of HSPA1A mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132
|
|
G |
Hspa1b |
heat shock protein 1B |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPA1B mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of HSPA1B mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr17:35,175,405...35,178,214
Ensembl chr17:35,175,412...35,178,214
|
|
G |
Hspa4 |
heat shock protein 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HSPA4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:53,150,641...53,191,306
Ensembl chr11:53,150,641...53,191,284
|
|
G |
Hspa4l |
heat shock protein 4 like |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HSPA4L mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:40,698,664...40,750,538
Ensembl chr 3:40,699,814...40,750,538
|
|
G |
Hspb1 |
heat shock protein 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HSPB1 mRNA] motexafin gadolinium results in increased expression of HSPB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417
|
|
G |
Hspd1 |
heat shock protein 1 (chaperonin) |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPD1 mRNA] motexafin gadolinium results in increased expression of HSPD1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402
|
|
G |
Hsph1 |
heat shock 105kDa/110kDa protein 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HSPH1 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HSPH1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 5:149,540,308...149,562,594
Ensembl chr 5:149,537,752...149,559,841
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of ID2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of ID2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:25,143,798...25,146,091
Ensembl chr12:25,143,798...25,147,139
|
|
G |
Ikbke |
inhibitor of kappaB kinase epsilon |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of IKBKE mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of IKBKE mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:131,182,337...131,207,339
Ensembl chr 1:131,182,080...131,207,344
|
|
G |
Irf2bp2 |
interferon regulatory factor 2 binding protein 2 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of IRF2BP2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of IRF2BP2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:127,315,035...127,320,725
Ensembl chr 8:127,315,035...127,320,725
|
|
G |
Jund |
jun D proto-oncogene |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of JUND mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of JUND mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:71,150,389...71,153,265
Ensembl chr 8:71,151,599...71,153,265
|
|
G |
Kdm3a |
lysine (K)-specific demethylase 3A |
increases expression |
ISO |
motexafin gadolinium results in increased expression of KDM3A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:71,565,954...71,609,963
Ensembl chr 6:71,565,956...71,609,974
|
|
G |
Klra17 |
killer cell lectin-like receptor, subfamily A, member 17 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of ZNF302 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:129,808,117...129,853,635
Ensembl chr 6:129,808,117...129,853,635
|
|
G |
Mdm2 |
transformed mouse 3T3 cell double minute 2 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of MDM2 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of MDM2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
|
|
G |
Mob1a |
MOB kinase activator 1A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of MOB1A mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of MOB1A mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 6:83,303,016...83,320,758
Ensembl chr 6:83,302,998...83,320,758
|
|
G |
Mt1 |
metallothionein 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of MT1X mRNA motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of MT1X mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of MT1X mRNA] |
CTD |
PMID:15867382 PMID:16357179 |
|
NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955
|
|
G |
Mt2 |
metallothionein 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of MT2A mRNA] motexafin gadolinium results in increased expression of MT2A mRNA |
CTD |
PMID:15867382 PMID:16357179 |
|
NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196
|
|
G |
Myd88 |
myeloid differentiation primary response gene 88 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of MYD88 mRNA motexafin gadolinium results in decreased expression of MYD88 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:119,165,000...119,169,084
Ensembl chr 9:119,165,000...119,170,477
|
|
G |
Nadk |
NAD kinase |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of NADK mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of NADK mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:155,646,838...155,675,458
Ensembl chr 4:155,646,835...155,675,458
|
|
G |
Nf1 |
neurofibromin 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of NF1 mRNA motexafin gadolinium results in increased expression of NF1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:79,223,541...79,472,435
Ensembl chr11:79,230,519...79,472,438
|
|
G |
Nisch |
nischarin |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of NISCH mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:30,892,885...30,928,783
Ensembl chr14:30,892,887...30,938,903
|
|
G |
Nr1d2 |
nuclear receptor subfamily 1, group D, member 2 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of NR1D2 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of NR1D2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr14:4,230,549...4,265,639
Ensembl chr14:4,230,569...4,265,642
|
|
G |
P4hb |
prolyl 4-hydroxylase, beta polypeptide |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of P4HB mRNA] motexafin gadolinium results in increased expression of P4HB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:120,451,124...120,464,079
Ensembl chr11:120,451,124...120,464,079
|
|
G |
Pdcd11 |
programmed cell death 11 |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of PDCD11 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:47,079,183...47,119,585
Ensembl chr19:47,079,207...47,120,304
|
|
G |
Pdcd4 |
programmed cell death 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PDCD4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PDCD4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:53,880,662...53,926,024
Ensembl chr19:53,880,662...53,918,291
|
|
G |
Pdcd5 |
programmed cell death 5 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of PDCD5 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of PDCD5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:35,341,410...35,346,907
Ensembl chr 7:35,341,407...35,346,946
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PFKFB3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PFKFB3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:11,476,241...11,558,882
Ensembl chr 2:11,476,244...11,558,888
|
|
G |
Pfkfb4 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PFKFB4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PFKFB4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:108,817,336...108,861,302
Ensembl chr 9:108,820,846...108,861,296
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PGK1 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PGK1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr X:105,230,706...105,247,305
Ensembl chr X:105,230,706...105,247,305
|
|
G |
Phtf2 |
putative homeodomain transcription factor 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PHTF2 mRNA] motexafin gadolinium results in increased expression of PHTF2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:20,963,662...21,087,122
Ensembl chr 5:20,963,661...21,087,122
|
|
G |
Pias1 |
protein inhibitor of activated STAT 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PIAS1 mRNA] motexafin gadolinium results in increased expression of PIAS1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:62,785,648...62,888,161
Ensembl chr 9:62,785,650...62,895,206
|
|
G |
Pik3ip1 |
phosphoinositide-3-kinase interacting protein 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PIK3IP1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PIK3IP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:3,280,731...3,292,971
Ensembl chr11:3,280,401...3,292,971
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PMAIP1 mRNA motexafin gadolinium results in increased expression of PMAIP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636
|
|
G |
Prkacb |
protein kinase, cAMP dependent, catalytic, beta |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PRKACB mRNA motexafin gadolinium results in increased expression of PRKACB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:146,435,334...146,518,691
Ensembl chr 3:146,435,329...146,518,745
|
|
G |
Prkcd |
protein kinase C, delta |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of PRKCD mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:30,317,310...30,348,637
Ensembl chr14:30,317,311...30,348,167
|
|
G |
Prkd2 |
protein kinase D2 |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of PRKD2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:16,576,827...16,604,386
Ensembl chr 7:16,576,827...16,604,389
|
|
G |
Prkdc |
protein kinase, DNA activated, catalytic polypeptide |
increases expression |
ISO |
motexafin gadolinium results in increased expression of PRKDC mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:15,455,698...15,660,103
Ensembl chr16:15,455,730...15,660,099
|
|
G |
Ptrh2 |
peptidyl-tRNA hydrolase 2 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of PTRH2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of PTRH2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:86,574,900...86,583,283
Ensembl chr11:86,574,811...86,583,283
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of RB1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of RB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:73,430,298...73,563,446
Ensembl chr14:73,421,113...73,563,262
|
|
G |
Rcbtb2 |
regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 2 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of RCBTB2 mRNA motexafin gadolinium results in decreased expression of RCBTB2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:73,376,185...73,421,495
Ensembl chr14:73,360,477...73,445,283
|
|
G |
Relb |
avian reticuloendotheliosis viral (v-rel) oncogene related B |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of RELB mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of RELB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:19,340,142...19,363,352
Ensembl chr 7:19,340,142...19,363,363
|
|
G |
Rnf19b |
ring finger protein 19B |
increases expression |
ISO |
motexafin gadolinium results in increased expression of RNF19B mRNA |
CTD |
PMID:15867382 |
|
NCBI chr 4:128,951,871...128,978,319
Ensembl chr 4:128,952,064...128,979,679
|
|
G |
Samtor |
S-adenosylmethionine sensor upstream of mTORC1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SAMTOR mRNA motexafin gadolinium results in increased expression of SAMTOR mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:13,625,674...13,677,965
Ensembl chr 6:13,625,672...13,677,965
|
|
G |
Selenow |
selenoprotein W |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SELENOW mRNA motexafin gadolinium results in increased expression of SELENOW mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:15,651,133...15,656,296
Ensembl chr 7:15,651,133...15,656,327
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions increases expression |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SESN2 mRNA; [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SESN2 mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SESN2 mRNA] motexafin gadolinium results in increased expression of SESN2 mRNA |
CTD |
PMID:16357179 PMID:20530418 |
|
NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812
|
|
G |
Slc16a1 |
solute carrier family 16 (monocarboxylic acid transporters), member 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC16A1 mRNA] motexafin gadolinium results in increased expression of SLC16A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:104,545,980...104,565,778
Ensembl chr 3:104,545,984...104,565,778
|
|
G |
Slc16a6 |
solute carrier family 16 (monocarboxylic acid transporters), member 6 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC16A6 mRNA motexafin gadolinium results in increased expression of SLC16A6 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:109,341,681...109,366,428
Ensembl chr11:109,341,681...109,364,424
|
|
G |
Slc1a4 |
solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC1A4 mRNA] motexafin gadolinium results in increased expression of SLC1A4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:20,252,180...20,282,713
Ensembl chr11:20,252,180...20,282,713
|
|
G |
Slc30a1 |
solute carrier family 30 (zinc transporter), member 1 |
multiple interactions increases expression |
ISO |
[Zinc co-treated with motexafin gadolinium] results in increased expression of SLC30A1 mRNA; motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC30A1 mRNA]; Zinc Acetate affects the reaction [motexafin gadolinium results in increased expression of SLC30A1 mRNA] |
CTD |
PMID:15867382 PMID:16357179 |
|
NCBI chr 1:191,638,810...191,645,359
Ensembl chr 1:191,638,879...191,645,359
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC38A2 mRNA]; Zinc Acetate affects the reaction [motexafin gadolinium results in increased expression of SLC38A2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr15:96,585,267...96,597,609
Ensembl chr15:96,585,273...96,597,611
|
|
G |
Slc39a10 |
solute carrier family 39 (zinc transporter), member 10 |
multiple interactions affects expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC39A10 mRNA motexafin gadolinium affects the expression of SLC39A10 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:46,846,704...46,964,952
Ensembl chr 1:46,846,704...46,932,012
|
|
G |
Slc39a14 |
solute carrier family 39 (zinc transporter), member 14 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of SLC39A14 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC39A14 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:70,540,916...70,588,873
Ensembl chr14:70,540,918...70,588,874
|
|
G |
Slc39a9 |
solute carrier family 39 (zinc transporter), member 9 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of SLC39A9 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC39A9 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:80,690,657...80,730,116
Ensembl chr12:80,690,657...80,730,116
|
|
G |
Slc3a2 |
solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC3A2 mRNA motexafin gadolinium results in increased expression of SLC3A2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:8,684,931...8,700,733
Ensembl chr19:8,684,246...8,700,733
|
|
G |
Slc43a1 |
solute carrier family 43, member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC43A1 mRNA motexafin gadolinium results in increased expression of SLC43A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:84,669,196...84,693,930
Ensembl chr 2:84,669,194...84,693,938
|
|
G |
Slc7a1 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC7A1 mRNA motexafin gadolinium results in increased expression of SLC7A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:148,264,220...148,336,714
Ensembl chr 5:148,264,220...148,336,714
|
|
G |
Slc7a11 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of SLC7A11 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC7A11 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063
|
|
G |
Smarca4 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of SMARCA4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SMARCA4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:21,527,377...21,615,526
Ensembl chr 9:21,527,465...21,615,526
|
|
G |
Smarca5 |
SNF2 related chromatin remodeling ATPase 5 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of SMARCA5 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SMARCA5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:81,426,572...81,466,088
Ensembl chr 8:81,425,136...81,466,126
|
|
G |
Tagap |
T cell activation Rho GTPase activating protein |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TAGAP mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TAGAP mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:8,144,832...8,153,729
Ensembl chr17:8,144,832...8,153,729
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of TFRC mRNA] motexafin gadolinium results in increased expression of TFRC mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612
|
|
G |
Tnfaip8 |
tumor necrosis factor, alpha-induced protein 8 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of TNFAIP8 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TNFAIP8 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:50,112,494...50,226,296
Ensembl chr18:50,112,494...50,240,240
|
|
G |
Tnfrsf17 |
tumor necrosis factor receptor superfamily, member 17 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TNFRSF17 mRNA motexafin gadolinium results in decreased expression of TNFRSF17 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:11,131,131...11,137,938
Ensembl chr16:11,131,676...11,137,938
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TNFRSF1A mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Tnfsf8 |
tumor necrosis factor (ligand) superfamily, member 8 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of TNFSF8 mRNA] motexafin gadolinium results in increased expression of TNFSF8 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:63,749,439...63,779,745
Ensembl chr 4:63,749,545...63,779,584
|
|
G |
Tnip2 |
TNFAIP3 interacting protein 2 |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of TNIP2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:34,653,440...34,671,323
Ensembl chr 5:34,653,431...34,671,335
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TRIB3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TRIB3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:152,179,345...152,185,980
Ensembl chr 2:152,179,342...152,185,952
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein; Acetylcysteine inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein]; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] |
CTD |
PMID:20530418 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TXNRD1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TXNRD1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of VEGFA mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of VEGFA mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vhl |
von Hippel-Lindau tumor suppressor |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of VHL mRNA] motexafin gadolinium results in increased expression of VHL mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:113,600,955...113,608,595
Ensembl chr 6:113,600,920...113,608,594
|
|